Pfizer Inc. (PFE)
PFE trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PFE on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000078003 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $62.6B |
| Net income | $7.8B |
| Operating income | Not in SEC XBRL data |
| Net margin | 12.4% |
| Operating margin | Operating income not reported |
| Revenue growth | -1.6% |
| Cash | $1.1B |
| Total assets | $208.2B |
| P/E (computed) | 21.2× |
| P/S (computed) | 2.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $1.8B cash; operating cash flow $3.5B a quarter. | Report 2026-09-27 |
| Shares outstanding | 5,699,853,733 (2026-10-28); 5,685,707,552 a year earlier; 5,646,413,292 three years earlier. | Cover page 2026-10-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2025-11-20 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, New York, New York, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $3.0M, sold $135K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-27 | $16.6B | $3.2B | $5.4B | $1.8B | $62.6B | $63.6B | 10-Q 2026-11-03 |
| Q2 2026 2026-06-28 | $15.0B | -$248.0M | $835.0M | $976.0M | $63.1B | $63.7B | 10-Q 2026-08-04 |
| Q1 2026 2026-03-29 | $14.5B | $2.7B | $2.6B | $1.7B | $64.4B | $63.3B | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $17.6B | -$1.6B | $5.3B | $1.1B | $64.6B | $62.6B | 10-K 2026-02-26 |
| Q3 2025 2025-09-28 | $16.7B | $3.5B | $4.6B | $1.3B | $61.7B | $62.8B | 10-Q 2026-11-03 |
| Q2 2025 2025-06-29 | $14.7B | $2.9B | -$582.0M | $1.6B | $61.7B | $63.8B | 10-Q 2026-08-04 |
| Q1 2025 2025-03-30 | $13.7B | $3.0B | $2.3B | $1.4B | $61.4B | $62.5B | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $17.8B | $410.0M | $6.7B | $1.0B | $61.2B | $63.6B | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-11-20 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-03-12 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.7% |
| 1 month | +1.8% |
| 3 months | +7.8% |
| Year to date | +16.0% |
| 1 year | +12.0% |
| From 52-week high | -6.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NVO | Novo Nordisk A/S | $41.60 | -0.07% | $184.2B |
| ABT | Abbott Laboratories | $107.45 | -0.99% | $186.1B |
| VRTX | Vertex Pharmaceuticals Incorporated | $537.79 | -0.15% | $136.4B |
| BMY | Bristol-Myers Squibb Company | $62.93 | -0.79% | $128.6B |
| SNY | Sanofi ADS | $48.39 | +0.04% | $118.0B |
| GSK | GSK plc | $50.41 | -0.08% | $102.0B |
| REGN | Regeneron Pharmaceuticals Inc. | $952.40 | -0.32% | $98.5B |
| AZN | AstraZeneca PLC | $184.02 | -0.23% | $285.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier